Hematology-Oncology – Page 5

Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia

By MedXY 09/22/2026

This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival and reduces leukemic burden.

Hematology-Oncology news Oncology

Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma

By MedXY 09/22/2026

PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.

Hematology-Oncology news Oncology

First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients

By MedXY 09/22/2026

The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid mantle cell lymphoma.

Critical Care Hematology-Oncology news

Incidence and Implications of Early Alloantibody Formation After Trauma Resuscitation With Rh(D)+ Whole Blood Versus Rh(D)- Red Blood Cells

By MedXY 09/21/2026

A large retrospective study demonstrates that transfusion of low-titer group O whole blood (LTOWB) in trauma resuscitation carries a low and comparable risk of early red blood cell alloimmunization relative to component therapy, including anti-D antibody formation.

Hematology-Oncology news Oncology

Distinct Roles of PD-L1 and PD-L2 in Primary Mediastinal Large B-Cell Lymphoma: Implications for Immune Therapeutics

By MedXY 09/20/2026

This article explores how PD-L1 and PD-L2 differentially regulate immune and lineage-specific programs in primary mediastinal large B-cell lymphoma, providing insights for tailored immunotherapy.

Hematology-Oncology news Rheumatology

Unraveling Neutrophil-Driven Interferonopathy in Hemophilic Arthropathy: A New Therapeutic Target

By MedXY 09/20/2026

This study identifies neutrophil-dependent type-I interferon responses and NETs as key drivers of joint damage in hemophilia A, opening avenues for novel therapies to prevent hemophilic arthropathy.

$Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin$

Hematology-Oncology news Oncology

Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin

By MedXY 09/20/2026

Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamicin. Allogeneic stem cell transplantation (allo-HSCT) benefits select high-risk patients.

Hematology-Oncology news

Contemporary Outcomes of Autologous Stem Cell Transplantation in AL Amyloidosis: Insights from a Decade-Long Multicenter Study

By MedXY 09/20/2026

A multicenter retrospective study of 1047 AL amyloidosis patients undergoing autologous stem cell transplantation (2010–2020) demonstrates improved safety, deep hematologic responses, and durable survival, affirming ASCT’s vital role in treatment paradigms.

Clinical Updates Hematology-Oncology news

Age, Anthracycline Use, and Mortality Outcomes in Classic Hodgkin Lymphoma: Insights from a Large Complete Population Cohort

By MedXY 09/20/2026

This review analyzes the impact of age and anthracycline-based chemotherapy on mortality in 28,000 classic Hodgkin lymphoma patients, highlighting poorer outcomes in the elderly and the therapeutic nuances influencing survival.

Hematology-Oncology news

CPX-351 versus CLAG-M in Medically Unfit Adults with AML: A Phase 2 Randomized Study Evaluating Survival and Response Outcomes

By MedXY 09/20/2026

This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive therapy benefits select subgroups.

Hematology-Oncology Neurology news

Unveiling the Systemic Drivers of Blood-Brain Barrier Disruption in Sickle Cell Disease: Insights from Proteomic Profiling

By MedXY 09/20/2026

This study identifies systemic pathological pathways that mediate blood-brain barrier injury in sickle cell disease, linking BBB disruption to brain hypoxia and microstructural injury, highlighting new therapeutic targets to preserve neurological function.

Hematology-Oncology news

Integrin αIIbβ3 Deficiency Impairs Platelet Formation Through Serine Metabolic Dysregulation in Megakaryocytes

By MedXY 09/20/2026

This study reveals that integrin αIIbβ3 deficiency in megakaryocytes disrupts serine metabolism, leading to reduced platelet production and shedding light on the complex pathophysiology underlying Glanzmann thrombasthenia.

Cardiology Hematology-Oncology news

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare Data

By MedXY 09/19/2026

Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitoring and preventive strategies.

Hematology-Oncology news

Optimizing Autologous Stem Cell Backup Mobilization with GCSF and Plerixafor in Sickle Cell Disease: Implications for Gene Therapy

By MedXY 09/18/2026

A retrospective study demonstrates the safety and efficacy of GCSF and plerixafor for CD34+ stem cell mobilization as autologous backup in sickle cell patients undergoing alternate donor HSCT, with insights relevant for gene therapy.

Hematology-Oncology news

Efficacy and Safety of All-Oral Ixazomib, Pomalidomide, and Dexamethasone in Triple-Class Exposed Multiple Myeloma: Insights from a Phase II Study

By MedXY 09/18/2026

This phase II study evaluates the all-oral ixazomib-pomalidomide-dexamethasone regimen in triple-class exposed relapsed/refractory multiple myeloma patients, demonstrating promising efficacy and manageable safety in an elderly and high-risk cohort.

Hematology-Oncology news

Asciminib as a Robust Treatment Option for BCR::ABL1 T315I-Mutated Chronic Myeloid Leukemia: Final Phase 1 Trial Outcomes

By MedXY 09/18/2026

Long-term phase 1 data confirm asciminib's efficacy and safety in treating CML-CP patients harboring the resistant BCR::ABL1 T315I mutation, with sustained major molecular responses and manageable adverse events over nearly six years.

Hematology-Oncology news

Harnessing Type-I Interferon-Activated NK Cells: A Novel Immunotherapeutic Approach to Polycythemia Vera

By MedXY 09/18/2026

This article explores how type-I interferon activates NK cells to control polycythemia vera progression, revealing insights into immune modulation and therapeutic potential in myeloproliferative neoplasms.

Hematology-Oncology news Oncology

Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults

By MedXY 09/18/2026

A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan regimens in selected cases.

Hematology-Oncology news Pediatrics

Gradual Maturation of the B-Cell Receptor Repertoire After Pediatric Hematopoietic Stem Cell Transplantation: Insights into Early Immune Reconstitution

By MedXY 09/18/2026

This study reveals early establishment of a diverse naïve B-cell receptor repertoire within 3 months post-pediatric HSCT, followed by gradual antigen-experienced maturation over 24 months, reflecting physiological B-cell development and supporting immune recovery strategies.

Hematology-Oncology news

Bendamustine as a Novel Single-Agent Therapy in High Burden T-Cell Large Granular Lymphocytic Leukemia: Clinical Efficacy and STAT3 Pathway Inhibition

By MedXY 09/18/2026

Bendamustine monotherapy achieved high response rates and inhibited STAT3 signaling in patients with high burden T-cell large granular lymphocytic leukemia, showing promise as an effective and well-tolerated treatment option.